ELYM · Categories · Form 4

ELYM - SEC Form 4 insider transactions

Eliem Therapeutics Inc (ELYM) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for ELYM

• 627d
  CHIEF ACCOUNTING OFFICER Pimblett Emily converted options into 5,000 shares and sold $9,741 worth of shares (1,191 units at $8.18), increasing direct ownership by 101% to 7,564 units (SEC Form 4)

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 652d
  SEC Form 4 filed by Chief Operating Officer Kaplan Brett

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 686d
  EVP, R&D AND CSO Morisset Valerie sold $988,495 worth of shares (129,206 units at $7.65), decreasing direct ownership by 80% to 31,317 units (SEC Form 4)

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 690d
  EVP, R&D AND CSO Morisset Valerie sold $289,492 worth of shares (41,783 units at $6.93), decreasing direct ownership by 21% to 160,523 units (SEC Form 4)

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 692d
  EVP, R&D AND CSO Morisset Valerie sold $356,500 worth of shares (50,000 units at $7.13), decreasing direct ownership by 20% to 202,306 units (SEC Form 4)

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 693d
  EVP, R&D AND CSO Morisset Valerie sold $650,563 worth of shares (92,377 units at $7.04), decreasing direct ownership by 27% to 252,306 units (SEC Form 4)

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 698d
  EVP, R&D AND CSO Morisset Valerie sold $736,500 worth of shares (105,931 units at $6.95), decreasing direct ownership by 24% to 344,683 units (SEC Form 4)

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 700d
  EVP, R&D AND CSO Morisset Valerie sold $87,135 worth of shares (12,342 units at $7.06), decreasing direct ownership by 3% to 450,614 units (SEC Form 4)

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 706d
  EVP, R&D AND CSO Morisset Valerie exercised 7,649 shares at a strike of $0.00 and sold $338,000 worth of shares (50,000 units at $6.76), decreasing direct ownership by 8% to 462,956 units (SEC Form 4)

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 711d
  SEC Form 4 filed by Director Ra Capital Management, L.P.

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 711d
  SEC Form 4 filed by Executive Chairman Levin Andrew David

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 711d
  SEC Form 4 filed by Director Rosenberg Adam Joseph

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 711d
  SEC Form 4 filed by Director Dunn Judith

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 711d
  SEC Form 4 filed by Director Tate Simon

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 711d
  SEC Form 4 filed by Director Ratcliffe Liam

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 712d
  SEC Form 4 filed by President and CEO Brennan Aoife

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 712d
  Director Thomas Stephen Basil was granted 103,907 shares (SEC Form 4)

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 718d
  CHIEF ACCOUNTING OFFICER Pimblett Emily converted options into 5,000 shares and sold $8,982 worth of shares (1,245 units at $7.21) (SEC Form 4)

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 792d
  Morisset Valerie exercised 17,847 shares at a strike of $0.00, increasing direct ownership by 4% to 505,307 units (SEC Form 4)

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 811d
  SEC Form 4 filed by Pimblett Emily

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 827d
  Morisset Valerie exercised 20,728 shares at a strike of $0.00, increasing direct ownership by 4% to 487,460 units (SEC Form 4)

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1114d
  SEC Form 4 filed by Ra Capital Management, L.P.

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1114d
  SEC Form 4 filed by Tate Simon

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1114d
  SEC Form 4 filed by Ratcliffe Liam

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1114d
  SEC Form 4 filed by Dunn Judith

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1114d
  SEC Form 4 filed by Rosenberg Adam Joseph

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1114d
  SEC Form 4 filed by Levin Andrew David

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1183d
  SEC Form 4: Morisset Valerie exercised 316,410 shares at a strike of $0.00, increasing direct ownership by 210% to 466,732 units

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1315d
  SEC Form 4 filed by Morisset Valerie

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1315d
  SEC Form 4 filed by Azelby Robert

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1315d
  SEC Form 4 filed by Bucher James B

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1315d
  SEC Form 4 filed by Lavelle Erin

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1469d
  SEC Form 4 filed by Tate Simon

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1469d
  SEC Form 4 filed by Ra Capital Management, L.P.

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1469d
  SEC Form 4 filed by Ratcliffe Liam

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1469d
  SEC Form 4 filed by Patterson Leone D

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1469d
  SEC Form 4 filed by Rosenberg Adam Joseph

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1469d
  SEC Form 4 filed by Levin Andrew David

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1469d
  SEC Form 4 filed by Dunn Judith

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1590d
  SEC Form 4 filed by Lavelle Erin

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1590d
  SEC Form 4 filed by Azelby Robert

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1590d
  SEC Form 4 filed by Morisset Valerie

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
• 1590d
  SEC Form 4 filed by Bucher James B

  4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)

Other ELYM categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends